{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T10:48:10Z","timestamp":1770461290958,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.conctc.2023.101061","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T19:46:34Z","timestamp":1673898394000},"page":"101061","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A platform trial approach to proof-of-concept (POC) studies in autism spectrum disorder: Autism spectrum POC initiative (ASPI)"],"prefix":"10.1016","volume":"32","author":[{"given":"J. Kyle","family":"Wathen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2632-7250","authenticated-orcid":false,"given":"Shyla","family":"Jagannatha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth","family":"Ness","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail","family":"Bangerter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0050-3575","authenticated-orcid":false,"given":"Gahan","family":"Pandina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.conctc.2023.101061_bib1","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","article-title":"Adaptive platform trials: definition, design, conduct and reporting considerations","volume":"18","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"22","key":"10.1016\/j.conctc.2023.101061_bib2","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMms1604593","article-title":"Assessing the gold standard--lessons from the history of RCTs","volume":"374","author":"Bothwell","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.conctc.2023.101061_bib3","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/jama.2015.2316","article-title":"The platform trial: an efficient strategy for evaluating multiple treatments","volume":"313","author":"Berry","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.conctc.2023.101061_bib4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1740774515626362","article-title":"Efficiencies of platform clinical trials: a vision of the future","volume":"13","author":"Saville","year":"2016","journal-title":"Clin. Trials"},{"key":"10.1016\/j.conctc.2023.101061_bib5","series-title":"Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry","year":"2018"},{"issue":"1","key":"10.1016\/j.conctc.2023.101061_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","article-title":"Adaptive designs in clinical trials: why use them, and how to run and report them","volume":"16","author":"Pallmann","year":"2018","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.conctc.2023.101061_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJMp1602256","article-title":"I-SPY 2--A glimpse of the future of phase 2 drug development?","volume":"375","author":"Harrington","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.conctc.2023.101061_bib8","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.conctc.2023.101061_bib9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12609-019-00334-2","article-title":"I-SPY 2: a neoadjuvant adaptive clinical trial designed to improve outcomes in high-risk breast cancer","volume":"11","author":"Wang","year":"2019","journal-title":"Curr Breast Cancer Rep"},{"key":"10.1016\/j.conctc.2023.101061_bib10","article-title":"Individualized screening trial of innovative glioblastoma Therapy (INSIGhT): a bayesian adaptive platform trial to develop precision medicines for patients with glioblastoma","volume":"3","author":"Alexander","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.conctc.2023.101061_bib11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1158\/1078-0432.CCR-17-0764","article-title":"Adaptive global innovative learning environment for glioblastoma: GBM AGILE","volume":"24","author":"Alexander","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.conctc.2023.101061_bib12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.14283\/jpad.2019.46","article-title":"The European prevention of alzheimer's dementia (EPAD) longitudinal cohort study: baseline data release V500.0","volume":"7","author":"Ritchie","year":"2020","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.conctc.2023.101061_bib13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fpsyt.2016.00188","article-title":"Defining precision medicine approaches to autism spectrum disorders: concepts and challenges","volume":"7","author":"Loth","year":"2016","journal-title":"Front. Psychiatr."},{"issue":"10","key":"10.1016\/j.conctc.2023.101061_bib14","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nrd4102","article-title":"Drug discovery for autism spectrum disorder: challenges and opportunities","volume":"12","author":"Ghosh","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"issue":"41","key":"10.1016\/j.conctc.2023.101061_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19410","article-title":"Systematic review of tools to measure outcomes for young children with autism spectrum disorder","volume":"19","author":"McConachie","year":"2015","journal-title":"Health Technol. Assess."},{"issue":"23","key":"10.1016\/j.conctc.2023.101061_bib16","doi-asserted-by":"crossref","first-page":"792","DOI":"10.21037\/atm.2019.11.53","article-title":"Emerging biomarkers in autism spectrum disorder: a systematic review","volume":"7","author":"Frye","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.conctc.2023.101061_bib17","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3389\/fnins.2017.00517","article-title":"JAKE(R) multimodal data capture system: insights from an observational study of autism spectrum disorder","volume":"11","author":"Ness","year":"2017","journal-title":"Front. Neurosci."},{"issue":"9","key":"10.1016\/j.conctc.2023.101061_bib18","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1089\/cap.2017.0018","article-title":"Autism behavior inventory: a novel tool for assessing core and associated symptoms of autism spectrum disorder","volume":"27","author":"Bangerter","year":"2017","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.conctc.2023.101061_bib19","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1007\/s10803-019-03965-7","article-title":"Clinical validation of the autism behavior inventory: caregiver-rated assessment of core and associated symptoms of autism spectrum disorder","volume":"50","author":"Bangerter","year":"2020","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.conctc.2023.101061_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12955-020-01665-w","article-title":"Qualitative evaluation of the Autism Behavior Inventory: use of cognitive interviewing to establish validity of a caregiver report scale for autism spectrum disorder","volume":"19","author":"Pandina","year":"2021","journal-title":"Health Qual. Life Outcome"},{"issue":"4","key":"10.1016\/j.conctc.2023.101061_bib21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/d41573-020-00012-4","article-title":"ASPI: a public-private partnership to develop treatments for autism","volume":"19","author":"Ness","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.conctc.2023.101061_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18020530","article-title":"The bayesian design of adaptive clinical trials","volume":"18","author":"Giovagnoli","year":"2021","journal-title":"Int. J. Environ. Res. Publ. Health"},{"issue":"1","key":"10.1016\/j.conctc.2023.101061_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/2229-516X.96789","article-title":"Use of Bayesian statistics in drug development: advantages and challenges","volume":"2","author":"Gupta","year":"2012","journal-title":"Int. J. Appl. Basic Med. Res."},{"key":"10.1016\/j.conctc.2023.101061_bib24","author":"Wathen"},{"issue":"1","key":"10.1016\/j.conctc.2023.101061_bib25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13063-021-05130-x","article-title":"Systematic review of available software for multi-arm multi-stage and platform clinical trial design","volume":"22","author":"Meyer","year":"2021","journal-title":"Trials"}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865423000078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865423000078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:07:08Z","timestamp":1762520828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865423000078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":25,"alternative-id":["S2451865423000078"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2023.101061","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A platform trial approach to proof-of-concept (POC) studies in autism spectrum disorder: Autism spectrum POC initiative (ASPI)","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2023.101061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101061"}}